Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.

@article{Neuhaus2002ImprovedTR,
  title={Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.},
  author={Peter Neuhaus and P M Clavien and Dilip Kittur and Mauro Salizzoni and Antoni Rimola and K. R. W. Abeywickrama and Elke Ortmann and Lawrence Chodoff and Michael G. Hall and Alexander Korn and Bjorn A P Nashan},
  journal={Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society},
  year={2002},
  volume={8 2},
  pages={132-42}
}
Basiliximab, a high-affinity chimeric monoclonal antibody, is effective in reducing acute rejection episodes in renal allograft recipients. We assessed the ability of this antibody to similarly improve the outcome in liver transplant recipients. Adult recipients of a primary cadaveric liver transplant were randomized to treatment, stratified by hepatitis C virus (HCV) seropositivity. Patients were administered 40 mg of basiliximab (n = 188) or placebo (n = 193) as two 20-mg bolus injections… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

CMV Primary Infection Is Associated With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2015
View 1 Excerpt

Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…